Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through Gero's AI-driven human data-first platform ...

Gero's physics-first AI drug discovery platform is transforming breakthroughs in the physics of aging into a pipeline of medicines designed to treat age-related diseases and slow the aging process ...

Funding by Melnichek Investments fuels Gero’s strategy to apply AI and real-world human health data to decode the relationship between aging and diseases, unravel their root causes, and create ...

Following a Chugai (Roche Group) collaboration with up to $250M in milestones in addition to royalties, and inspired by mammals that defy the rules of aging, Gero uses physics-first AI and human ...

GERO and FOXO share the goal of helping people live healthier for longer, whether through the development of new diagnostics and therapeutics, or by lifestyle modifications. FOXO’s founding was based, ...

People who know Naledi are perpetually aware of two things: he is a talented visual artist, and he has seen copious amounts of anime. Dr. Gero's family, including his wife Vomi and grandson Dr. Hedo, ...

TOKYO, July 07, 2025 (GLOBE NEWSWIRE) -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter "Chugai"), and Gero PTE. LTD. (hereafter "Gero"), a Singapore-based biotechnology company, announced ...